The approval follows October 2024's indication extension for daratumumab-VRd for newly diagnosed patients eligible for ASCT.

After a six-week trial in 2024, relators' counsel Pete Marketos of Reese Marketos and Sherrie Savett of Berger Montague ...

Halozyme (HALO) announced that Janssen-Cilag International, a Johnson & Johnson (JNJ) company, received European Commission approval for an ...

Beerse: Janssen-Cilag International NV, a Johnson & Johnson company, has received approval from the European Commission (EC) ...

Following hot on the heels of Monday’s European Commission EC approval of an indication extension for Johnson & Johnson’s ...

Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Commission has approved an extension of marketing ...

Janssen Products LP must pay over $1.6 billion in a False Claims Act suit for improperly billing the US government for HIV ...

New compelling results demonstrate 18 months of both sustained reduction in immunoglobulin G antibodies and sustained improvement in gMG symptoms in pivotal Vivacity-MG3 study and open label extension ...

Dr Edmond Chan, senior director EMEA therapeutic area lead, haematology, at Janssen-Cilag Limited, said: “Despite advances, there remains a high unmet need for those with heavily pre-treated ...

Janssen-Cilag International NV has announced results from the phase 3 MARIPOSA study, demonstrating a significant overall ...